A vaccine against nicotine being tested in Switzerland helped nearly 60% of smokers who achieved a high level of antibodies stop smoking for at least six months, according to researchers at the University of Lausanne. Four companies reportedly are studying nicotine vaccines, including Cytos Biotechnology of Zurich, whose vaccine was tested, Xenova Group of Britain and U.S. firms Nabi Biopharmaceuticals and Prommune.

Related Summaries